Venlafaxine
- Generic Name
- Venlafaxine
- Brand Names
- Effexor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO2
- CAS Number
- 93413-69-5
- Unique Ingredient Identifier
- GRZ5RCB1QG
- Background
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...
- Indication
Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.
- Associated Conditions
- Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Mendel AI
- Target Recruit Count
- 60
- Registration Number
- NCT04737967
- Locations
- 🇪🇬
Faculty of Medicine Cairo University - Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine, Cairo, Egypt
Acupuncture for Prophylaxis of Vestibular Migraine
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Affiliated Hospital of Jiaxing University
- Target Recruit Count
- 72
- Registration Number
- NCT04664088
- Locations
- 🇨🇳
The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China
Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT04639193
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute Building, La Jolla, California, United States
🇺🇸UCSD Health - Pulmonary and Sleep Clinic, La Jolla, California, United States
Pragmatic Trial of Obsessive-compulsive Disorder
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1600
- Registration Number
- NCT04539951
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 40
- Registration Number
- NCT04218123
- Locations
- 🇺🇸
Medical Univeristy of South Carolina, Charleston, South Carolina, United States
Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT04207385
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shanxi, China
Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT03574792
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Bariatric Surgery and Pharmacokinetics of Venlafaxine
- Conditions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03532477
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.